anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Cerebral ischemia-reperfusion (I/R) injury is a common complication of ischemic stroke, with autophagy and pyroptosis playing key roles. Huangqi and Danggui (HQDG) are a commonly used drug pair of Chinese traditional medicine for clinical treatment of ischemic stroke.
AIM OF THE STUDY: The study aims to investigate the interaction between autophagy and pyroptosis regulated by HQDG through the AMPK/mTOR signaling pathway during cerebral I/R injury.
MATERIALS AND METHODS: Model of middle-cerebral artery occlusion/reperfusion (MCAO/R) in SD rats was established using the Longa suture method. The components of traditional Chinese medicine were detected by liquid chromatography coupled to quadrupole orbitrap high resolution mass spectrometry (LC/MS). Neurological deficits were evaluated by neurological function score. Changes of cerebral blood flow were detected by a laser speckle blood flow imaging instrument. The volume of cerebral infarction was observed by 2,3,5-Chlorotriphenyltetrazolium (TTC) staining. The permeability of the blood-brain barrier was measured by Evans blue test. Neurovascular unit and autophagosomes in brain tissue were assessed by transmission electron microscopy. Neuronal pyroptosis was detected by terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL)/Caspase-1 staining. The expression of autophagy related proteins, pyroptosis related proteins, and AMPK/mTOR pathway related proteins were detected by Western blot.
RESULTS: After cerebral I/R injury, autophagy and pyroptosis, were characterized by increased number of autophagosomes and pyroptosis cells, upregulated expression of Beclin 1, LC3-II/LC3-I, NLRP3, cleaved Caspase-1, IL-1beta, IL-18 proteins, and downregulated expression of P62 proteins. HQDG significantly improved neurological function, reduced the volume of cerebral infarction, increased cerebral blood flow, improved blood-brain barrier permeability and the function of neurovascular units. Autophagy was further activated and pyroptosis was significantly inhibited by HQDG, which promoted increased number of autophagosomes, enhanced expression of Beclin 1, LC3-II/LC3-I proteins, reduced expression of P62, NLRP3, cleaved Caspase-1, IL-1beta, and IL-18 proteins, and downregulated the number of pyroptosis cells. On the other hand, after administering 3-Methyladenine (3-MA) to inhibit autophagy, the above effects of HQDG were significantly inhibited. Besides, HQDG promoted AMPK phosphorylation, and weakened mTOR phosphorylation. However, after the administration of AMPK inhibitor Compound C, HQDG caused increase in Beclin 1 and LC3-II/LC3-I, reduced P62 and NLRP3, and cleaved Caspase-1 protein expression, whereas cerebral blood flow decreased.
CONCLUSION: HQDG alleviated pyroptosis by promoting autophagy via AMPK/mTOR signaling pathway after middle-cerebral artery occlusion/reperfusion in rats, showing its potential for treatment of cerebral I/R injury in humans.
VAX102 is a cross-protective influenza A vaccine based on a recombinant protein expressed in E. coli. The protein comprises Salmonella typhimurium flagellin type 2 (STF2; TLR5 ligand) fused to Human M2e. The active component of the VAX102 vaccine is manufactured by a standard fermentation process. Unlike the HA and NA viral proteins, the amino acid sequence of M2e has remained remarkably stable in all human influenza A virus isolates. Thus an influenza vaccine based on the M2e antigen could elicit cross-protective immunity against most human influenza A virus strains. VAX102 vaccine relies on a single cross-reactive influenza A virus antigen manufactured by a recombinant protein fermentation-production process.
PURPOSE:To provide a powdery oil or fat composition containing gamma-linolenic acid, obtained by compounding a gamma-linolenic acid-containing oil or fat with cyclodextrin, suppressing the oxidization of oil or fat with cyclodextrin, suppressing the oxidization of oil or fat by the inclusion effect and utilizabel easily as a health food or medicinal drug. CONSTITUTION:The objective composition contains gamma-linolenic acid-containing oil or fat (e.g. primrose oil) an cyclodextrin. gamma-Linolenic acid is known as an essential fatty acid (vitamic F) which is an intermediate in the conversion of linolic acid to prostaglandin (abbreviated as PG) and participating in various physiological actions of PG as a PG precursor. Since the oil or fat gas liquid form, it is necessary to be administered in the form of e.g. a soft capsule, which restricts the application of the oil. An oil or fat composition containing gamma- linolenic acid having high oil or fat content and excellent oxidation stability can be produced by selecting cyclodextrin as the pulverization base of the oil, etc., and clathrating and pulverizing the mixture in the presence of water.
The present invention provides a method using manioca seeds to prepare a protective agent for preventing schistosoma japonicum infection, which relates to the method using the manioca seeds to prepare the protective agent for preventing schistosoma japonicum infection. In the present invention, after manioca fruit is cleaned, dried, distilled in a forced circulation mode and extracted in a reflux mode, extracting clear solution is concentrated; then, manufacturing techniques of biologic fermentation, etc. are carried out to concentrate to prepare the product. The protective agent has low toxicity to aquatic animals and good protection function to schistosoma japonicum and can also prevent leeches from biting parasitifer skin. The instant contact disinsection effective rates of the protective agent are all 100%, the contact death rate of schistosoma japonicum cercaria in 8 min is 100%, the protection rate of cercaria infection animal experiments is 100% after the protective agent is smeared, the protection effect can last for 4 to 8h after water flush and mud milling, the protective rate on site is 100%, and the present invention has no toxic or side effect to healthy rats. The present invention has the advantages of no stimulation, no poison, low price, convenient use and no environment pollution.
FIELD: medicine. SUBSTANCE: invention relates to the development of the inhalation form of an antiasthmatic agent. Invention proposes the inhalation antiasthmatic agent containing beta-carotene and vehicle. Lactose or lactose in combination with galactose can be used as a vehicle. The agent is simple and available, shows low toxicity and bronchodilating and antiallergic effects. EFFECT: enhanced effectiveness of the agent. 2 cl, 2 tbl, 1 dwg
Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
In some embodiments, provided herein are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein are methods of treating a sleep disorder associated with pain in a patient in need thereof, the method comprising: a) identifying a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein are methods of treating a sleep disorder associated with pain in a patient in need thereof, the method comprising: a) selecting a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the sleep disorder is selected from the group consisting of: difficulty in falling asleep; sleep disturbance; comfort is difficult to obtain; difficulty in maintaining sleep; a degree of deep sleep; degree of rest when waking up during the day; difficulty starting a new day; and the degree to which sleep was adequate during the previous late phase. In some embodiments, the sleep disorder is associated with pain selected from the group consisting of: fibromyalgia, neuropathic pain, osteoarthritis, and visceral pain. In some embodiments, the visceral pain is selected from the group consisting of IBS-associated pain and bladder pain.
Bariatric surgery (BS) has been as a currently developed treatment of choice for metabolic syndrome (MetS). Which, in turn, is well-known as serious public health concern. Therefore, this study assessed the outcomes of different procedures of BS and possible predictors for improving MetS. This single-center retrospective cohort analysis included bariatric candidates between 2009 and 2017. The operational approach was chosen based on the patient's condition, as well as the patient's metabolic profile and the surgeon's experience. All desired information was evaluated at baseline and 6, 12, and 24 months after the operation. Of the 1111 patients included, 918 (82.6%) were female. There was no considerable trend in the improvement of MetS over the follow-up period of each surgery group. After 6 to 24 months of follow-up, waist circumference reduction was significant in all three types of surgery, and sleeve gastrectomy resulted in the best (but not significant) improvement rates after 24 months (P = 0.079). One anastomosis gastric bypass had highest decrease in percentage of excess weight loss than other procedures (P < 0.001). Each year increase in age was associated with a 4% decrease in MetS remission. In addition, the male gender, was correlated with MetS improvement positively (P = 0.049). Each one-unit increase in hemoglobin A1c (HbA1c) reduced the MetS remission rate by 40%. All three methods of BS were similarly effective in MetS. Consider the predictive value of age, gender, and HbA1c before determining the optimum procedure for each patient is recommended.
The efficacy of TECENTRIQ HYBREZA as monotherapy for the treatment of adult patients with unresectable or metastatic alveolar soft part sarcoma (ASPS) has been established in adequate and well-controlled studies of intravenous atezolizumab for ASPS. TECENTRIQ HYBREZA is not indicated for the treatment of pediatric patients. Below is a description of the efficacy of intravenous atezolizumab in this adequate and well-controlled ASPS trial.

The efficacy of intravenous atezolizumab was evaluated in study ML39345 (NCT03141684), an open-label, single-arm study, in 49 adult and pediatric patients aged 2 years and older with unresectable or metastatic ASPS. Although this study enrolled pediatric patients, TECENTRIC HYBREZA is not indicated for use in pediatric patients. Eligible patients were required to have histologically or cytologically confirmed ASPS that was not curable by surgery, and an ECOG performance status of ≤ 2.

Patients were excluded if they had known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, known clinically significant liver disease, or history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.

Adult patients received 1200 mg intravenously and pediatric patients received 15 mg/kg (up to a maximum of 1200 mg) intravenously once every 21 days until disease progression or unacceptable toxicity.

The major efficacy outcomes were Overall Response Rate (ORR) and Duration of Response (DOR) by Independent Review Committee according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

A total of 49 patients were enrolled. The median age of patients was 31 years (range: 12–70); 2% of adult patients (n = 47) were ≥ 65 years of age and the pediatric patients (n = 2) were ≥ 12 years of age; 51% of patients were female, 55% White, 29% Black or African American, 10% Asian; 53% had an ECOG performance status of 0 and 45% had an ECOG performance status of 1. All patients had prior surgery for ASPS and 55% received at least one prior line of treatment for ASPS; 55% received radiotherapy and 53% received chemotherapy. Of the patients who reported staging at initial diagnosis, all were Stage IV.

Efficacy results of this study are summarized in Table 31.
PROBLEM TO BE SOLVED: To provide a method for screening compounds or polypeptides inhibiting the activity of a human airway-specific trypsin-like enzyme(AST) or inhibiting the activation of a protease activated receptor(PAR) by the AST, to provide a method for assaying the AST in cells or samples existing in or obtained from living body, and to provide therapeutic agents for diseases caused by AST activation. SOLUTION: This AST is a protein composed of part or the whole of human- or mouse-derived specific amino acid sequences or a protein haying >=66% homology with human-derived specific amino acid sequences, wherein the propeptide segments and trypsin-like protein segments are respectively linked to each other through disulfide linkages. The 2nd objective nucleic acid encoding the AST is provided. The 3rd objective antibody bindable to the nucleic acid is provided. The 4th objective method for assaying the AST using such an antibody is provided. The 5th objective method for assaying the AST inhibitory activity of a to-be-assayed compound or polypeptide or the inhibitory activity of PAR activation by the AST is provided. The 6th objective therapeutic agents each with such an inhibitory polypeptide as the main medicinal ingredient are provided.
Self-monitoring of blood glucose using capillary glucose testing (C) has a number of shortcomings compared to continuous glucose monitoring (CGM). We aimed to compare these two methods and used blood glucose measurements in venous blood (IV) as a reference. Postprandial blood glucose levels were measured after 50 g oral glucose load and after the consumption of a portion of different foods containing 50 g of carbohydrates. We also evaluated the associations between postprandial glucose responses and the clinical characteristics of the participants at the beginning of the study. Incremental area under the curve (AUCi) of postprandial blood glucose was calculated for 1 h (AUCi 0-60) and 2 h (AUCi 0-120). Despite considerable inter-individual variability of postprandial glycemic responses, CGM evaluated postprandial glycemic excursions which had comparable results compared to standard blood glucose measurements under real-life conditions.
Gastric cancer is one of the most common digestive tumors in the world.In China, advanced gastric cancer with severe local progression or distant metastasis is more common.Gastric cancer with peritoneal carcinomatosis has an extremely poor prognosis,with a median survival of less than 6 months.Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is currently a treatment for malignant tumors in the abdominal cavity and prevents tumor recurrence and metastasis.Studies have shown that hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) has good clinical efficacy in the prevention and treatment of peritoneal metastasis of gastric cancer and its associated malignant ascites.Therefore,we conduct a single-centre randomized controlled trial to explore the safety and feasibility of HIPEC in the treatment of advanced gastric cancer with peritoneal metastasis. The metahnism of HIPEC is taking advantage of the difference in temperature sensitivity between cancer cells and normal cells. Perfusion of the abdominal cavity with a chemical fluid of the appropriate temperature can be performed. Suitable high temperatures can directly kill tumor cells.It is generally believed that the optimal temperature for the treatment of tumors is 42.5°C to 44°C.In this study,we set the temperature 43°C. Paclitaxel is a novel broad-spectrum antitumor drug,which has a unique anti-cancer mechanism.We use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs.The chemotherapy is SOX(Teggio and Oxaliplatin),.The primary endpoint is PFS. Secondary endpoints are one-year OS、canversion rate and ascites assessment. A phase III study PHOENIX-GC trial had finished enrollment,and the conclusion was the median OS 17.7 and 15.2 months respectively for IP and SP.The primary analysis did not show the statistical superiority of the IP regimen.The sensitivity analysis IP considering the imbalance of ascites, suggested clinical efficacy of IP PTX in gastric cancer with peritoneal metastasis. For this reason,we conduct a trial to explore the safety and feasibility of HIPEC in the treatment of advanced gastric cancer with peritoneal metastasis.
In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
This is a randomised multicentre clinical feasibility and pilot trial, where assessors and statisticians will be blinded. Forty-four participants with moderate to severe traumatic brain injury will be randomised to INSPIRE versus standard care as soon as they are able to understand and execute simple commands twice during one day. Participants in the INSPIRE group will undergo two weeks of intensive sit-to-stand exercise using an algorithm to increase the intensity daily. The trial uses predefined dose-limiting events to reduce training intensity in participants experiencing exercise-related adverse events that limit other daily activities and rehabilitation (e.g. muscle soreness and pain). Overall feasibility will be assessed by determining the inclusion rate, exercise completion rate, and completion of the Glasgow Outcome Scale - Extended. As exploratory clinical outcomes, the investigators will assess serious adverse events and adverse events not considered serious, physical function, cardiovascular and metabolic health, fatigue, and cognitive function.
In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
To compare the Scanning Laser Polarimetry findings in subjects with exfoliation syndrome and normal controls and to evaluate the value of scanning laser polarimetry in the early diagnosis and management of exfoliative glaucoma. Prospective study in progress. The investigators compare and analyze the scanning laser polarimetry parameters in consecutive subjects with exfoliation syndrome and normal intraocular pressure and compared them with consecutive normal controls. Randomly selected patients with exfoliation syndrome and normal controls undergo a comprehensive ophthalmic exam which includes 3 IOP measurements, corneal pachymetry, automated perimetry and assessment of the retina nerve fiber layer with scanning laser polarimetry. The investigators hypothesize that patients with exfoliation syndrome may show worse scanning laser polarimetry parameters than normal controls and this may prove to be an early sign of exfoliative glaucoma development. Evaluation of retina nerve fiber layer thickness may help us in identifying earlier those individuals with exfoliation syndrome that will develop exfoliative glaucoma.
DRESS, also known as multi-organ hypersensitivity, has been reported with armodafinil. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though rash is not evident.

One fatal case of DRESS that occurred in close temporal association (3 weeks) with the initiation of armodafinil treatment has been reported in the postmarketing setting. In addition, multi-organ hypersensitivity reactions, including at least one fatality in postmarketing experience, have occurred in close temporal association (median time to detection 13 days; range 4-33) to the initiation of modafinil. Although there have been a limited number of reports, multi-organ hypersensitivity reactions may result in hospitalization or be life-threatening.

If a multi-organ hypersensitivity reaction is suspected, armodafinil should be discontinued. Although there are no case reports to indicate cross-sensitivity with other drugs that produce this syndrome, the experience with drugs associated with multi-organ hypersensitivity would indicate this to be a possibility.
In Cohort B, subjects in the ascending dose group all received PM IV drip administered at a frequency of BiW (2 times per week) for 2 consecutive weeks, i.e., on days 1, 4, 8, and 11 of each cycle, with a 1-week discontinuation for a 21-day cycle (with a minimum interval of ≥48 h between each of the 2 doses in the same dosing cycle). Tirelizumab was administered as 200 mg IV every 3 weeks, administered on the first day of each cycle. Based on the results obtained during the dose-escalation phase, the need for and the dose of the Phase IIa expansion cohort will be determined after discussion by the Safety Management Committee (SMC), and the Phase IIa cohort expansion is expected to select 1-2 dosage groups of 10-15 cases each.
A method includes detecting a condition including one or more of a change in flow of a fluid and d change in a composition of the fluid, issuing an alarm in response to the condition detected, lowering a flow rate; and attempting to restart process and increase the flow rate. The change in flow may include a change in pressure. The change in flow may be associated with a collapsed vein. The change in flow of the fluid may include detecting that the flow rate has fallen below a threshold. The change in the composition may be associated with a color. The change in the composition may include using a color sensor to detect one or more of a red, a green, and a blue reflection or transmission to detect red blood cells.
A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof . The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed. *
All participants in this study will receive YTB323. Both the participant and the study doctor will know the participant is getting YTB323. Participants will be given one dose of YTB323. Different groups of participants may receive a higher dose of YTB323, if proven to be safe for every participant at the lower dose. Participants are in this study for 2 years and will be followed for an additional 13 years in a long-term follow up study. The main question this trial is designed to answer: Is YTB323 treatment safe for participants with relapsing MS?